Clinical trial
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced…
NCT00323583 · Seattle Cancer Treatment and Wellness Center, Other · Unknown status
Key facts
| NCT number | NCT00323583 |
|---|---|
| Title | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer |
| Official title | Phase II Study of Paclitaxel, Oxaliplatin, Leucovorin and 5-Fluorouracil (POLF) in Gemcitabine-Refractory Advanced Pancreatic Cancer |
| Lead sponsor | Seattle Cancer Treatment and Wellness Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarincoma of Pancreas, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer |
| Intervention type | Drug, Procedure |
| Interventions | paclitaxel, oxaliplatin, leucovorin, 5-fluorouracil, glutathione, calcium and magnesium, Chemotherapy, Chemoprotection, Complementary and alternative therapy |
| Enrollment | 80 |
| Start date | May 1, 2006 |
| First posted | May 9, 2006 |
| Last update posted | May 8, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: